본문 바로가기
KERD
논문KCI 등재

The development of mesenchymal stem cell therapy in the present, and the perspective of cell-free therapy in the future

Yusuke Watanabe|Atsunori Tsuchiya|Shuji Terai
대한간학회 (The korean Association for the Study of the Liver)|2021.01|Clinical and Molecular Hepatology|제27권 제1호|pp. 70-80|DOI 10.3350/cmh.2020.0194

2

조회

0

다운로드

4

인용

0

참고문헌

키워드

Mesenchymal stem cellsCirrhosisMacrophagesExosomesExtracellular vesicles

초록

Cirrhosis is a chronic condition that can lead to liver failure. Currently, the viable option for decreasing mortality is liver transplantation. However, transplant surgery is highly invasive. Therefore, cell-based therapy has been developed as an alternative. Based on promising findings from preclinical research, some new trials have been registered. One of them was autologous bone marrow cell infusion therapy and found that ameliorating liver fibrosis activated liver regeneration. Now, majority of trials focus on low-immunogenicity mesenchymal stem cells (MSCs) appropriate for allogeneic administration. However, despite about 20 years of research, only a limited number of cell-based therapies have entered routine practice. Furthermore, potential shortcomings of cell-based therapy include a limit on the number of cells, which may be administered, as well as their failure to infiltrate target organs. On the other hand, these research show that MSCs act as “conducting cells” and regulate host cells including macrophages via extracellular vesicles (EVs) or exosome signals, leading to ameliorate liver fibrosis and promote regeneration. Therefore, the concept of cell-free therapy, which makes use of cell-derived EVs or exosomes, is attracting attention. Cell-free therapies may be safely administered in large doses and are able to infiltrate target organs. However, development of cell-free therapy exhibits its own set of challenges and such therapy may not be completely curative in the context of liver disease. This review describes the history of cell-based therapy research and recent advances in cell-free therapy, as well as discussing the need for more effective therapies.

Abstract

Cirrhosis is a chronic condition that can lead to liver failure. Currently, the viable option for decreasing mortality is liver transplantation. However, transplant surgery is highly invasive. Therefore, cell-based therapy has been developed as an alternative. Based on promising findings from preclinical research, some new trials have been registered. One of them was autologous bone marrow cell infusion therapy and found that ameliorating liver fibrosis activated liver regeneration. Now, majority of trials focus on low-immunogenicity mesenchymal stem cells (MSCs) appropriate for allogeneic administration. However, despite about 20 years of research, only a limited number of cell-based therapies have entered routine practice. Furthermore, potential shortcomings of cell-based therapy include a limit on the number of cells, which may be administered, as well as their failure to infiltrate target organs. On the other hand, these research show that MSCs act as “conducting cells” and regulate host cells including macrophages via extracellular vesicles (EVs) or exosome signals, leading to ameliorate liver fibrosis and promote regeneration. Therefore, the concept of cell-free therapy, which makes use of cell-derived EVs or exosomes, is attracting attention. Cell-free therapies may be safely administered in large doses and are able to infiltrate target organs. However, development of cell-free therapy exhibits its own set of challenges and such therapy may not be completely curative in the context of liver disease. This review describes the history of cell-based therapy research and recent advances in cell-free therapy, as well as discussing the need for more effective therapies.

참고문헌 (99)

  1. Tsochatzis EA, "Liver cirrhosis", Lancet, 383, pp.1749~1761 (2014)
  2. Asrani SK, "Burden of liver diseases in the world", J Hepatol, 70, pp.151~171 (2019)
  3. Tateishi R, "A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update", J Gastroenterol, 54, pp.367~376 (2019)
  4. Tang LSY, "Chronic hepatitis B infection:a review", JAMA, 319, pp.1802~1813 (2018)
  5. Jang JW, "Longterm effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis", Hepatology, 61, pp.1809~1820 (2015)
  6. Curry MP, "Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis", N Engl J Med, 373, pp.2618~2628 (2015)
  7. Terai S, "Status of and candidates for cell therapy in liver cirrhosis: overcoming the “point of no return” in advanced liver cirrhosis", J Gastroenterol, 52, pp.129~140 (2017)
  8. Mokdad AA, "Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis", BMC Med, 12, pp.145~ (2014)
  9. Toniutto P, "Challenges and future developments in liver transplantation", Minerva Gastroenterol Dietol, 65, pp.136~152 (2019)
  10. Forbes SJ, "Cell therapy for liver disease: from liver transplantation to cell factory", J Hepatol, 62(1 Suppl), pp.S157~S169 (2015)
  11. Merion RM, "The survival benefit of liver transplantation", Am J Transplant, 5, pp.307~313 (2005)
  12. Schuppan D, "Liver fibrosis: direct antifibrotic agents and targeted therapies", Matrix Biol, 68(69), pp.435~451 (2018)
  13. Sanyal AJ, "Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis", N Engl J Med, 362, pp.1675~1685 (2010)
  14. Traber PG, "Regression of fibrosis and reversal of cirrhosis in rats by galectin inhibitors in thioacetamide-induced liver disease", PLoS One, 8, pp.e75361~ (2013)
  15. Granzow M, "Angiotensin-II type 1 receptor-mediated Janus kinase 2 activation induces liver fibrosis", Hepatology, 60, pp.334~348 (2014)
  16. Rozenfeld R, "AT1R-CB1R heteromerization reveals a new mechanism for the pathogenic properties of angiotensin II", EMBO J, 30, pp.2350~2363 (2011)
  17. Ueno T, "Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis", Exp Ther Med, 2, pp.1035~1040 (2011)
  18. Moreno M, "Ghrelin attenuates hepatocellular injury and liver fibrogenesis in rodents and influences fibrosis progression in humans", Hepatology, 51, pp.974~985 (2010)
  19. Puthawala K, "Inhibition of integrin alpha(v)beta6, an activator of latent transforming growth factor-beta, prevents radiation-induced lung fibrosis", Am J Respir Crit Care Med, 177, pp.82~90 (2008)
  20. Henderson NC, "Targeting of αv integrin identifies a core molecular pathway that regulates fibrosis in several organs", Nat Med, 19, pp.1617~1624 (2013)
  21. Gao B, "Liver natural killer and natural killer T cells: immunobiology and emerging roles in liver diseases", J Leukoc Biol, 86, pp.513~528 (2009)
  22. Chakraborty JB, "NF-kappaB signalling: embracing complexity to achieve translation", J Hepatol, 52, pp.285~291 (2010)
  23. Kamiya A, "Fetal liver development requires a paracrine action of oncostatin M through the gp130 signal transducer", EMBO J, 18, pp.2127~2136 (1999)
  24. Boulter L, "Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease", Nat Med, 18, pp.572~579 (2012)
  25. Peng L, "Autologous bone marrow mesenchymal stem cell transplantation in liver failure patients caused by hepatitis B: short-term and long-term outcomes", Hepatology, 54, pp.820~828 (2011)
  26. Sakaida I, "Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice", Hepatology, 40, pp.1304~1311 (2004)
  27. Terai S, "Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy", Stem Cells, 24, pp.2292~2298 (2006)
  28. Terai S, "Current status of autologous bone marrow cell infusion therapy for liver cirrhosis patients", Hepatol Res, 38(Suppl 1), pp.S72~S75 (2008)
  29. Terai S, "Timeline for development of autologous bone marrow infusion (ABMi) therapy and perspective for future stem cell therapy", J Gastroenterol, 47, pp.491~497 (2012)
  30. Saito T, "Potential therapeutic application of intravenous autologous bone marrow infusion in patients with alcoholic liver cirrhosis", Stem Cells Dev, 20, pp.1503~1510 (2011)
  31. Kim JK, "Autologous bone marrow infusion activates the progenitor cell compartment in patients with advanced liver cirrhosis", Cell Transplant, 19, pp.1237~1246 (2010)
  32. Nakamura T, "Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model", Gastroenterology, 133, pp.91~107.e1 (2007)
  33. Salama H, "Autologous hematopoietic stem cell transplantation in 48 patients with end-stage chronic liver diseases", Cell Transplant, 19, pp.1475~1486 (2010)
  34. Wang Y, "Plasticity of mesenchymal stem cells in immunomodulation: pathological and therapeutic implications", Nat Immunol, 15, pp.1009~1016 (2014)
  35. Zhou BO, "Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow", Cell Stem Cell, 15, pp.154~168 (2014)
  36. Prockop DJ, "Mesenchymal stem", stromal cells (MSCs): role as guardians of inflammation, 2012, pp.20, 14~20
  37. Sica A, "Macrophage plasticity and polarization: in vivo veritas", J Clin Invest, 122, pp.787~795 (2012)
  38. Duffield JS, "Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair", J Clin Invest, 115, pp.56~65 (2005)
  39. Bruno S, "Microvesicles derived from mesenchymal stem cells enhance survival in a lethal model of acute kidney injury", PLoS One, 7, pp.e33115~ (2012)
  40. Parekkadan B, "Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure", PLoS One, 2, pp.e941~ (2007)
  41. Iwamoto T, "Bone-marrow-derived cells cultured in serum-free medium reduce liver fibrosis and improve liver function in carbon-tetrachloridetreated cirrhotic mice", Cell Tissue Res, 351, pp.487~495 (2013)
  42. Tanimoto H, "Improvement of liver fibrosis by infusion of cultured cells derived from human bone marrow", Cell Tissue Res, 354, pp.717~728 (2013)
  43. Terai S, "Status and prospects of liver cirrhosis treatment by using bone marrow-derived cells and mesenchymal cells", Tissue Eng Part B Rev, 20, pp.206~210 (2014)
  44. Banas A, "Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes", Hepatology, 46, pp.219~228 (2007)
  45. Seki A, "Adipose tissue-derived stem cells as a regenerative therapy for a mouse steatohepatitis-induced cirrhosis model", Hepatology, 58, pp.1133~1142 (2013)
  46. Shiratsuki S, "Enhanced survival of mice infused with bone marrow-derived as compared with adipose-derived mesenchymal stem cells", Hepatol Res, 45, pp.1353~1359 (2015)
  47. Shi M, "Human mesenchymal stem cell transfusion is safe and improves liver function in acute-onchronic liver failure patients", Stem Cells Transl Med, 1, pp.725~731 (2012)
  48. Zhang Z, "Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients", J Gastroenterol Hepatol, 27(Suppl 2), pp.112~120 (2012)
  49. Wang L, "Pilot study of umbilical cord-derived mesenchymal stem cell transfusion in patients with primary biliary cirrhosis", J Gastroenterol Hepatol, 28(Suppl 1), pp.85~92 (2013)
  50. Wang L, "Allogeneic bone marrow mesenchymal stem cell transplantation in patients with UDCA-resistant primary biliary cirrhosis", Stem Cells Dev, 23, pp.2482~2489 (2014)
  51. Sharpe PT, "Dental mesenchymal stem cells", Development, 143, pp.2273~2280 (2016)
  52. Ikarashi S, "Effects of human adipose tissue-derived and umbilical cord tissue-derived mesenchymal stem cells in a dextran sulfate sodiuminduced mouse model", Biores Open access, 8, pp.185~199 (2019)
  53. Kawata Y, "Early injection of human adipose tissue-derived mesenchymal stem cell after inflammation ameliorates dextran sulfate sodiuminduced colitis in mice through the induction of M2 macrophages and regulatory T cells", Cell Tissue Res, 376, pp.257~271 (2019)
  54. Volarevic V, "Mesenchymal stem cell-derived factors: immuno-modulatory effects and therapeutic potential", Biofactors, 43, pp.633~644 (2017)
  55. Ma OK, "Immunomodulation by mesenchymal stem cells:interplay between mesenchymal stem cells and regulatory lymphocytes", World J Stem Cells, 8, pp.268~278 (2016)
  56. Pinheiro D, "Mechanisms underlying cell therapy in liver fibrosis: an overview", Cells, 8, pp.1339~ (2019)
  57. Tsuchiya A, "Mesenchymal stem cell therapies for liver cirrhosis: MSCs as “conducting cells” for improvement of liver fibrosis and regeneration", Inflamm Regen, 39, pp.18~ (2019)
  58. Tsuchiya A, "Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases", Inflamm Regen, 37, pp.16~ (2017)
  59. Kojima Y, "Mesenchymal stem cells cultured under hypoxic conditions had a greater therapeutic effect on mice with liver cirrhosis compared to those cultured under normal oxygen conditions", Regen Ther, 11, pp.269~281 (2019)
  60. Watanabe T, "Development of a non-alcoholic steatohepatitis model with rapid accumulation of fibrosis, and its treatment using mesenchymal stem cells and their small extracellular vesicles", Regen Ther, 14, pp.252~261 (2020)
  61. Watanabe Y, "Mesenchymal stem cells and induced bone marrow-derived macrophages synergistically improve liver fibrosis in mice", Stem Cells Transl Med, 8, pp.271~284 (2019)
  62. Thomas JA, "Macrophage therapy for murine liver fibrosis recruits host effector cells improving fibrosis, regeneration, and function", Hepatology, 53, pp.2003~2015 (2011)
  63. Kim J, "Mesenchymal stem cell-educated macrophages:a novel type of alternatively activated macrophages", Exp Hematol, 37, pp.1445~1453 (2009)
  64. Eggenhofer E, "Mesenchymal stem cell-educated macrophages", Transplant Res, 1, pp.12~ (2012)
  65. Maggini J, "Mouse bone marrow-derived mesenchymal stromal cells turn activated macrophages into a regulatory-like profile", PLoS One, 5, pp.e9252~ (2010)
  66. Kharaziha P, "Improvement of liver function in liver cirrhosis patients after autologous mesenchymal stem cell injection: a phase I-II clinical trial", Eur J Gastroenterol Hepatol, 21, pp.1199~1205 (2009)
  67. Jang YO, "Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study", Liver Int, 34, pp.33~41 (2014)
  68. Suk KT, "stem cells for alcoholic cirrhosis: phase 2 trial", Hepatology, 64, pp.2185~2197 (2016)
  69. Xu L, "Randomized trial of autologous bone marrow mesenchymal stem cells transplantation for hepatitis B virus cirrhosis: regulation of Treg", Th17 cells, 2014, pp.29, 1620~1628
  70. Moroni F, "Safety profile of autologous macrophage therapy for liver cirrhosis", Nat Med, 25, pp.1560~1565 (2019)
  71. Maas SL, "Quantification and size-profiling of extracellular vesicles using tunable resistive pulse sensing", J Vis Exp, (92), pp.e51623~ (2014)
  72. Gnecchi M, "Paracrine mechanisms of mesenchymal stem cells in tissue repair", Methods Mol Biol, 1416, pp.123~146 (2016)
  73. Braicu C, "Exosomes as divine messengers: are they the Hermes of modern molecular oncology?", Cell Death Differ, 22, pp.34~45 (2015)
  74. Zhou Y, "Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro", Stem Cell Res Ther, 4, pp.34~ (2013)
  75. Arslan F, "Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K", Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia, Stem Cell Res, pp.2013, 10[DOI]
  76. Bian S, "Extracellular vesicles derived from human bone marrow mesenchymal stem cells promote angiogenesis in a rat myocardial infarction model", J Mol Med (Berl), 92, pp.387~397 (2014)
  77. Teng X, "Mesenchymal stem cell-derived exosomes improve the microenvironment of infarcted myocardium contributing to angiogenesis and anti-inflammation", Cell Physiol Biochem, 37, pp.2415~2424 (2015)
  78. Rager TM, "Exosomes secreted from bone marrow‐derived mesenchymal stem cells protect the intestines from experimental necrotizing enterocolitis", J Pediatr Surg, 51, pp.942~947 (2016)
  79. Lee C, "Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia‐induced pulmonary hypertension", Circulation, 126, pp.2601~2611 (2012)
  80. Aliotta JM, "Exosomes induce and reverse monocrotaline-induced pulmonary hypertension in mice", Cardiovasc Res, 110, pp.319~330 (2016)
  81. Zhu YG, "Human mesenchymal stem cell microvesicles for treatment of Escherichia coli endotoxin‐induced acute lung injury in mice", Stem Cells, 32, pp.116~125 (2014)
  82. Xin H, "Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats", J Cereb Blood Flow Metab, 33, pp.1711~1715 (2013)
  83. Ophelders DR, "Mesenchymal stromal cell-derived extracellular vesicles protect the fetal brain after hypoxia-ischemia", Stem Cells Transl Med, 5, pp.754~763 (2016)
  84. Zhang B, "HucMSCexosome mediated‐Wnt4 signaling is required for cutaneous wound healing", Stem Cells, 33, pp.2158~2168 (2015)
  85. Zhang B, "Human umbilical cord mesenchymal stem cell exosomes enhance angiogenesis through the Wnt4", β-catenin pathway, 2015, pp.4, 513~522
  86. Shabbir A, "Mesenchymal stem cell exosomes induce proliferation and migration of normal and chronic wound fibroblasts, and enhance angiogenesis in vitro", Stem Cells Dev, 24, pp.1635~1647 (2015)
  87. Blazquez R, "Immunomodulatory potential of human adipose mesenchymal stem cells derived exosomes on in vitro stimulated T cells", Front Immunol, 5, pp.556~ (2014)
  88. Zhang B, "Mesenchymal stem cells secrete immunologically active exosomes", Stem Cells Dev, 23, pp.1233~1244 (2014)
  89. Reis LA, "Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats", PLoS One, 7, pp.e44092~ (2012)
  90. Doeppner TR, "Extracellular vesicles improve post-stroke neuroregeneration and prevent postischemic immunosuppression", Stem Cells Transl Med, 4, pp.1131~1143 (2015)
  91. 최문환, "Therapeutic Use of Stem Cell Transplantation for Cell Replacement or Cytoprotective Effect of Microvesicle Released from Mesenchymal Stem Cell", Molecules and Cells, 37(2), pp.133~139 (2014), 한국분자세포생물학회[DOI]
  92. Tan CY, "Mesenchymal stem cell-derived exosomes promote hepatic regeneration in druginduced liver injury models", Stem Cell Res Ther, 5, pp.76~ (2014)
  93. Li T, "Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis", Stem Cells Dev, 22, pp.845~854 (2013)
  94. Jiang L, "Exosomes derived from human umbilical cord mesenchymal stem cells alleviate acute liver failure by reducing the activity of the NLRP3inflammasome in macrophages", Biochem Biophys Res Commun, 508, pp.735~741 (2019)
  95. Haga H, "Extracellular vesicles from bone marrow-derived mesenchymal stem cells improve survival from lethal hepatic failure in mice", Stem Cells Transl Med, 6, pp.1262~1272 (2017)
  96. Povero D, "Human induced pluripotent stem cell-derived extracellular vesicles reduce hepatic stellate cell activation and liver fibrosis", JCI Insight, 5, pp.e125652~ (2019)
  97. Borrelli DA, "Extracellular vesicle therapeutics for liver disease", J Control Release, 273, pp.86~98 (2018)
  98. Imai T, "Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice", J Extracell Vesicles, 4, pp.26238~ (2015)
  99. Batrakova EV, "Using exosomes, naturally-equipped nanocarriers, for drug delivery", J Control Release, 219, pp.396~405 (2015)

관련 논문AI추천

Mesenchymal Stem Cells for the Treatment of Liver Disease: Present and Perspectives엄영우, Moon Young Kim, Seong Hee Kang, Soon Koo Baik거트앤리버 소화기연관학회협의회 · Gut and Liver2020 · 제14권 제3호Stem cell exosomes: new hope and future potential for relieving liver fibrosisChong Jin, Hao Jiang, Jinggang Mo, Kunpeng Wang, Lihua Li, Yongjie Liu, Zhiyong Weng대한간학회 · Clinical and Molecular Hepatology2025 · 제31권 제2호Mesenchymal Stem Cell-derived Exosomes: Applications in Cell-free Therapy김진관, 허준석대한임상검사과학회 · 대한임상검사과학회지2018 · 제50권 제4호Mesenchymal Stem Cell Therapy in Acute Liver FailureChen En-Qiang, Wang Yong-Hong거트앤리버 소화기연관학회협의회 · Gut and Liver2023 · 제17권 제5호Inhibition of hepatic stellate cells by bone marrow-derived mesenchymal stem cells in hepatic fibrosis권상옥, 김문영, 백순구, 장윤옥, 전백규대한간학회 · Clinical and Molecular Hepatology2015 · 제21권 제2호Usage of Human Mesenchymal Stem Cells in Cell-based Therapy: Advantages and Disadvantages김희정, 박정수한국발생생물학회 · 발생과 생식2017 · 제21권 제1호

이 간행물의 다른 논문 (23건)

Current understanding of primary biliary cholangitisAtsushi Tanakapp. 1-21The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver diseaseChristopher D. Byrne, Erica Jennisonpp. 22-43Updates in the quantitative assessment of liver fibrosis for nonalcoholic fatty liver disease: Histological perspectiveAileen Wee, Gwyneth Soonpp. 44-57Recent updates on the management of autoimmune hepatitisAtsumasa Komoripp. 58-69Drug-drug interactions with direct-acting antivirals — less is moreGrace Lai-Hung Wongpp. 81-82
원문 보기